OS Therapies (OSTX) News Today $1.84 +0.03 (+1.66%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.89 +0.05 (+2.72%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock OSTX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period OS Therapies Stock Surges 12.4% After Positive FDA Feedback on OST-HER2June 24, 2025 | msn.comOS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaJune 24, 2025 | businesswire.comOS Therapies Announces Warrant Exercise Inducement & Exchange OfferJune 23, 2025 | businesswire.comOS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic OsteosarcomaJune 10, 2025 | prnewswire.comOSTX OS Therapies IncorporatedJune 1, 2025 | seekingalpha.comBuy Rating for OS Therapies: Promising Developments and Strategic Positioning in Cancer ImmunotherapyMay 21, 2025 | tipranks.comOS Therapies Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 16, 2025 | businesswire.comOS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine OsteosarcomaMay 15, 2025 | finance.yahoo.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Shalom Auerbach Sells 82,000 SharesMay 10, 2025 | insidertrades.comOS Therapies Inc sees $163,918 in stock sales by major shareholderMay 9, 2025 | investing.comOS Therapies secures patent for cancer immunotherapy techMay 8, 2025 | investing.comEmmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer TherapiesMay 2, 2025 | businesswire.comOS Therapies granted FDA meeting for OST-HER2April 22, 2025 | markets.businessinsider.comOS Therapies FDA Meeting Request GrantedApril 22, 2025 | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $67,516.20 in StockApril 12, 2025 | insidertrades.comOS Therapies Announces Positive Data From The Study Of OST-HER2 In Osteosarcoma In DogsApril 12, 2025 | nasdaq.comOS Therapies Inc: Shalom Auerbach sells $81,566 in common stockApril 11, 2025 | investing.comOS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in HumansApril 10, 2025 | businesswire.comOS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala PharmaceuticalsApril 9, 2025 | businesswire.comLake Street Initiates Coverage of OS Therapies (OSTX) with Buy RecommendationApril 3, 2025 | msn.comOS Therapies Inc Reports 2024 Net Loss Per Share of $0. ...April 1, 2025 | gurufocus.comOS Therapies Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 31, 2025 | businesswire.comOS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human OsteosarcomaMarch 31, 2025 | businesswire.comOS Therapies’ OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersMarch 25, 2025 | finance.yahoo.comOS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer PioneersMarch 25, 2025 | businesswire.comOS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to AnalystsMarch 23, 2025 | insidermonkey.comOS Therapies to Attend The Jones Healthcare and Technology Innovation ConferenceMarch 21, 2025 | businesswire.comOS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma ConferenceMarch 13, 2025 | businesswire.comOS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3March 11, 2025 | markets.businessinsider.comSpin-Offs as Catalysts: Unlocking Value, Driving Growth, and Creating Opportunities for Big GainsMarch 4, 2025 | theglobeandmail.comJoin OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27February 26, 2025 | finance.yahoo.comJoin OS Therapies' Exclusive Live Investor Webinar and Q&A Session on February 27February 26, 2025 | businesswire.comOS Therapies receives patent notice of allowance for OST-HER2February 20, 2025 | markets.businessinsider.comOS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2February 20, 2025 | businesswire.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $284,000.00 in StockFebruary 19, 2025 | insidertrades.comOSTX Stock Earnings: OS Therapies Reported Results for Q2 2024February 14, 2025 | investorplace.comOS Therapies gears up for FDA meeting on cancer drugFebruary 14, 2025 | msn.comOS Therapies initiates commercial manufacturing of OST-HER2February 14, 2025 | markets.businessinsider.comSmall-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone CancerFebruary 14, 2025 | benzinga.comOS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) FilingFebruary 14, 2025 | businesswire.comOS Therapies gears up for osteosarcoma drug approvalFebruary 4, 2025 | msn.comOS Therapies Provides Corporate UpdateFebruary 4, 2025 | businesswire.comOS Therapies files to sell 10.83M shares of common stock for holdersFebruary 1, 2025 | markets.businessinsider.comOS Therapies Inc trading resumesJanuary 30, 2025 | markets.businessinsider.comOS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral CapitalJanuary 30, 2025 | marketbeat.comOS Therapies Inc's Lock-Up Period Will Expire on January 28th (NYSE:OSTX)January 21, 2025 | marketbeat.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $112,692.80 in StockJanuary 18, 2025 | insidertrades.comos therapies sees $112,609 in stock sales by Einodmil LLCJanuary 17, 2025 | msn.comShalom Auerbach Sells 16,720 Shares of OS Therapies Inc (NYSE:OSTX) StockJanuary 17, 2025 | marketbeat.comOS Therapies price target raised to $15 from $8 at MaximJanuary 17, 2025 | finance.yahoo.com Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address OSTX Media Mentions By Week OSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OSTX News Sentiment▼0.280.94▲Average Medical News Sentiment OSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OSTX Articles This Week▼42▲OSTX Articles Average Week Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Inhibrx News Today scPharmaceuticals News Today Monopar Therapeutics News Today Genfit News Today I-Mab News Today CARGO Therapeutics News Today 4D Molecular Therapeutics News Today ProQR Therapeutics News Today Bright Minds Biosciences News Today CytomX Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:OSTX) was last updated on 6/28/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Shocking Link Between A.I. and Your MoneyThe AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and u...Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.